BioCentury
ARTICLE | Financial News

LSP closes fifth fund at $280 million

June 3, 2016 12:53 AM UTC

LSP closed its fifth fund, LSP 5, at a hard cap of $280 million, well above its initial target of $170 million. The firm plans to invest LSP 5 with the same strategy as previous funds, targeting investments in about 20 therapeutic, diagnostic and medical device companies primarily in Europe.

LSP Managing Partner Rene Kuijten told BioCentury the fund's capital consists of 40% from institutional LPs, 22% from strategic investors, including Bristol-Myers Squibb Co. (NYSE:BMY), and 38% from family offices and individual investors (see BioCentury Extra, Nov. 24, 2015). ...